Ranolazine and silent ischemia

Journal of the American College of Cardiology

Volumn 58, Issue 10, 2011, Pages 1083-

  Conti, C Richard ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANOLAZINE; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CHANNEL;

CALCIUM CELL LEVEL; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; DRUG MECHANISM; ELECTROCARDIOGRAM; HEART MUSCLE ISCHEMIA; HUMAN; LETTER; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRIORITY JOURNAL; SILENT MYOCARDIAL ISCHEMIA; SODIUM CELL LEVEL; SODIUM CURRENT; ST SEGMENT DEPRESSION; STABLE ANGINA PECTORIS;

ACETANILIDES; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MYOCARDIAL ISCHEMIA; PIPERAZINES;

EID: 80052093901     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.11.084     Document Type: Letter

References (3)

1. P.H. Stone, B.R. Chaitman, K. Stocke, J. Sano, A. DeValut, and G.G. Koch The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease J Am Coll Cardiol 56 2010 934 942
2. D.T. Nash, and S.D. Nash Ranolazine for chronic stable angina Lancet 372 2008 1335 1341
3. D.A. Morrow, B.M. Scirica, E. Karwatowska-Prokopczuk MERLIN-TIMI 36 Trial Investigators Effects of ranolazine on recurrent cardiovascular events in patients with nonST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial JAMA 297 2007 1775 1783 (Pubitemid 46658646)